BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23187803)

  • 1. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.
    Leontieva OV; Lenzo F; Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2012 Dec; 11(24):4642-9. PubMed ID: 23187803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK drives cyclin D1 hyperelevation during geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
    Leontieva OV; Natarajan V; Demidenko ZN; Burdelya LG; Gudkov AV; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13314-8. PubMed ID: 22847439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.
    Stein GH; Drullinger LF; Soulard A; Dulić V
    Mol Cell Biol; 1999 Mar; 19(3):2109-17. PubMed ID: 10022898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth stimulation leads to cellular senescence when the cell cycle is blocked.
    Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2008 Nov; 7(21):3355-61. PubMed ID: 18948731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin, proliferation and geroconversion to senescence.
    Blagosklonny MV
    Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin decelerates cellular senescence.
    Demidenko ZN; Zubova SG; Bukreeva EI; Pospelov VA; Pospelova TV; Blagosklonny MV
    Cell Cycle; 2009 Jun; 8(12):1888-95. PubMed ID: 19471117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate.
    Romanov VS; Abramova MV; Svetlikova SB; Bykova TV; Zubova SG; Aksenov ND; Fornace AJ; Pospelova TV; Pospelov VA
    Cell Cycle; 2010 Oct; 9(19):3945-55. PubMed ID: 20935470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells.
    Shen H; Maki CG
    J Biol Chem; 2010 Jul; 285(30):23105-14. PubMed ID: 20489208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.
    Leontieva OV; Blagosklonny MV
    Oncotarget; 2014 Dec; 5(24):12715-27. PubMed ID: 25587030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.
    Blagosklonny MV
    Aging (Albany NY); 2012 Mar; 4(3):159-65. PubMed ID: 22394614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin.
    Leontieva OV; Demidenko ZN; Gudkov AV; Blagosklonny MV
    PLoS One; 2011; 6(10):e26126. PubMed ID: 22022534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S6K in geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2013 Oct; 12(20):3249-52. PubMed ID: 24036549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
    Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
    Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.
    Blagosklonny MV
    Cell Cycle; 2011 Jul; 10(14):2295-8. PubMed ID: 21715978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical suppression of cellular senescence by p53.
    Demidenko ZN; Korotchkina LG; Gudkov AV; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2010 May; 107(21):9660-4. PubMed ID: 20457898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.
    Huang S; Liu LN; Hosoi H; Dilling MB; Shikata T; Houghton PJ
    Cancer Res; 2001 Apr; 61(8):3373-81. PubMed ID: 11309295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.